PT1718322E - Composições sinérgicas com fk-228 - Google Patents

Composições sinérgicas com fk-228 Download PDF

Info

Publication number
PT1718322E
PT1718322E PT05719967T PT05719967T PT1718322E PT 1718322 E PT1718322 E PT 1718322E PT 05719967 T PT05719967 T PT 05719967T PT 05719967 T PT05719967 T PT 05719967T PT 1718322 E PT1718322 E PT 1718322E
Authority
PT
Portugal
Prior art keywords
antitumor agent
antitumor
synergistic compositions
agent
dna
Prior art date
Application number
PT05719967T
Other languages
English (en)
Inventor
Yoshinori Naoe
Takeshi Inoue
Yasuhiko Kano
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT1718322E publication Critical patent/PT1718322E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT05719967T 2004-02-25 2005-02-25 Composições sinérgicas com fk-228 PT1718322E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004050520 2004-02-25
US56607704P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
PT1718322E true PT1718322E (pt) 2011-09-05

Family

ID=34889383

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05719967T PT1718322E (pt) 2004-02-25 2005-02-25 Composições sinérgicas com fk-228

Country Status (11)

Country Link
US (2) US7951780B2 (pt)
EP (1) EP1718322B1 (pt)
JP (1) JP4930055B2 (pt)
AT (1) ATE516041T1 (pt)
CA (1) CA2557540A1 (pt)
CY (1) CY1111926T1 (pt)
DK (1) DK1718322T3 (pt)
PL (1) PL1718322T3 (pt)
PT (1) PT1718322E (pt)
SI (1) SI1718322T1 (pt)
WO (1) WO2005079827A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1426054B1 (en) * 2001-08-21 2011-09-28 Astellas Pharma Inc. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
EP1492596A1 (en) * 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
MXPA05008904A (es) * 2003-02-19 2005-10-05 Astellas Pharma Inc Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
US7314862B2 (en) * 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
AU2006311894A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Method of treating cancers with SAHA and pemetrexed
WO2007061939A2 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP2012801A4 (en) * 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc GEMCITABINE COMBINATION THERAPY
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2073837B1 (en) * 2006-10-06 2014-06-25 Bavarian Nordic Inc. Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
JP2010514801A (ja) * 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンの精製
EP2556838A1 (en) * 2006-12-29 2013-02-13 Gloucester Pharmaceuticals, Inc. Romidepsin-based treatments for cancer
US9156792B2 (en) * 2008-05-09 2015-10-13 University Of Maryland, Baltimore Retinamide and uses thereof
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
CA2801891C (en) * 2010-06-07 2020-10-27 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
US20120190817A2 (en) 2010-07-12 2012-07-26 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN106860872B (zh) * 2017-01-18 2019-03-22 上海交通大学 用于逆转肿瘤对铂类抗癌药多药耐药性的两亲性药-药纳米颗粒药物及其制备方法与应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
JPH0315810A (ja) * 1989-06-13 1991-01-24 Minolta Camera Co Ltd カメラ
AU734476B2 (en) * 1997-11-05 2001-06-14 Baylor College Of Medicine Sequences for targeting metastatic cells
CA2386876A1 (en) * 1999-11-10 2001-05-17 Warner-Lambert Company Combination chemotherapy
DE60011678T2 (de) * 1999-12-08 2005-07-14 Xcyte Therapies, Inc., Seattle Depsipeptide und deren analoge zur verwendung als immunosuppressiva
DE60137932D1 (de) 2000-07-17 2009-04-23 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US7396665B2 (en) 2000-09-01 2008-07-08 Astellas Pharma, Inc. Method of producing FR901228
EP1355566B1 (en) * 2000-12-18 2012-11-28 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6620816B2 (en) * 2001-04-26 2003-09-16 Bristol-Myers Squibb Company Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
EP1426054B1 (en) 2001-08-21 2011-09-28 Astellas Pharma Inc. Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
EE200400074A (et) * 2001-08-31 2004-06-15 Bristol-Myers Squibb Company Koostised ning nende kasutamine proliferatiivsetehaiguste raviks
EP1293205A1 (en) 2001-09-18 2003-03-19 G2M Cancer Drugs AG Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
EP1492596A1 (en) 2002-04-05 2005-01-05 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
WO2003088954A1 (en) 2002-04-15 2003-10-30 Sloan-Kettering Institute For Cancer Research Combination therapy for the treatment of cancer
PA8578001A1 (es) * 2002-08-07 2004-05-07 Warner Lambert Co Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
MXPA05008904A (es) 2003-02-19 2005-10-05 Astellas Pharma Inc Metodo para estimar el efecto antitumoral del inhibidor de desacetilasa de histona.
PL2238982T3 (pl) 2003-06-27 2013-03-29 Astellas Pharma Inc Środek do terapii mięsaka tkanek miękkich
CA2472842C (en) 2003-07-22 2012-05-29 Honda Motor Co., Ltd. Working machine
US7314862B2 (en) 2003-09-25 2008-01-01 Astellas Pharma Inc. Antitumor agent
US20050187148A1 (en) 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
EP1718322A2 (en) 2006-11-08
ATE516041T1 (de) 2011-07-15
US7951780B2 (en) 2011-05-31
CA2557540A1 (en) 2005-09-01
WO2005079827A3 (en) 2005-12-08
US20110160295A1 (en) 2011-06-30
JP4930055B2 (ja) 2012-05-09
WO2005079827A2 (en) 2005-09-01
CY1111926T1 (el) 2015-11-04
PL1718322T3 (pl) 2011-12-30
US8822422B2 (en) 2014-09-02
EP1718322B1 (en) 2011-07-13
US20050187149A1 (en) 2005-08-25
DK1718322T3 (da) 2011-08-29
SI1718322T1 (sl) 2011-09-30
JP2007524650A (ja) 2007-08-30

Similar Documents

Publication Publication Date Title
PT1718322E (pt) Composições sinérgicas com fk-228
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
MXPA06003222A (es) Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
WO2007030409A3 (en) In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine and derivatives
WO2007054573A3 (en) Anti-proliferative combination therapy comprising a platinum-based chemotherapeutic agent and egfr inhibitors or pyrimidine analogues
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
WO2006061258A3 (en) Cytotoxic agents comprising new taxanes
WO2007126832A3 (en) Pharmaceutical compositions for prevention of overdose or abuse
MX2008010801A (es) Indolopiridinas como moduladores de quinesina eg5.
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
NO20073026L (no) 2-alkoksy-3,4,5-trihydroksy-alkylamider, fremstilling og sammensetninger derav samt anvendelse derav
PL1591514T3 (pl) Zastosowanie dodatków do poprawy zapachu kompozycji węglowodorów oraz kompozycje węglowodorów zawierające takie dodatki
GB2437149B (en) Synergistic preservative systems and their use in cosmetic compositions.
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2007124382A3 (en) Inhaled imipenem
SI1883647T1 (sl) Oligonukleotid in obsegajoča ga sestava za zdravljenje B celične neoplazme
EP2357003A4 (en) ANTICANCER COMPOSITION COMPRISING ANTITUMOR SUBSTANCE AND AGENT AND HAVING INHIBITORY EFFECTS ON L1CAM ACTIVITY AND EXPRESSION
MY139425A (en) Pharmaceutical composition comprising 2,4-dichlorobenzyl alcohol and amylmetacresol
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
WO2009047434A3 (fr) Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant
TW200503676A (en) Use of kynurenine 3-hydroxylase inhibitors for the treatment of diabetes